Arnold L Alper, MD in Amherst, MA - Ophthalmology

Arnold L Alper, MD is a Ophthalmology physician based in Amherst, Massachusetts. Arnold L Alper is licensed to practice in Massachusetts (license number 79471) and his current practice location is 117 Cherry Ln, Amherst, Massachusetts. He can be reached at his office (for appointments etc.) via phone at (413) 549-0438.

NPI number for Arnold L Alper is 1548382617 and his current mailing address is 117 Cherry Ln, Amherst, Massachusetts. He does not participate in medicare program and thus does not accept medicare assignments. His NPI Number is 1548382617.

Contact Information

	Arnold L Alper, MD
	117 Cherry Ln, Amherst, MA 01002-4401
	(413) 549-0438
	Not Available

Physician's Profile

Full Name	Arnold L Alper
Gender	Male
Speciality	Ophthalmology
Location	117 Cherry Ln, Amherst, Massachusetts
Accepts Medicare Assignments	Does not participate in Medicare Program. He may not accept medicare assignment.

NPI Data:

NPI Number: 1548382617
Provider Enumeration Date: 04/06/2007
Last Update Date: 07/08/2007

Medical Identifiers

Medical identifiers for Arnold L Alper such as npi, medicare ID, medicare PIN, medicaid, etc.

Identifier	Type	State	Issuer
1548382617	NPI	-	NPPES

Medical Taxonomies and Licenses

Taxonomy	Type	License (State)	Status
207W00000X	Ophthalmology	79471 (Massachusetts)	Primary

Medicare Part D Prescriber Enrollment

Any physician or other eligible professional who prescribes Part D drugs must either enroll in the Medicare program or opt out in order to prescribe drugs to their patients with Part D prescription drug benefit plans. Arnold L Alper is NOT enrolled with medicare and thus cannot prescribe medicare part D drugs to patients with medicare part D benefits.

Mailing Address and Practice Location

Mailing Address	Practice Location Address
Arnold L Alper, MD 117 Cherry Ln, Amherst, MA 01002-4401 Ph: (413) 549-0438	Arnold L Alper, MD 117 Cherry Ln, Amherst, MA 01002-4401 Ph: (413) 549-0438

News Archive

Collegium completes Type A meeting with FDA for COL-003 Phase III chronic low back pain study

Collegium Pharmaceutical, Inc., a specialty pharmaceutical company, announced today that it has successfully completed a Type A meeting with the U.S. Food and Drug Administration (FDA) regarding the proposed Phase III clinical study for COL-003, the Company's tamper-resistant, extended release oxycodone product utilizing its proprietary DETERx technology.

Comprehensive program to help reduce health risks of narcotics drugs on injured workers

Accident Fund Holdings, Inc. recently created a comprehensive narcotics program to help reduce the health risks of these drugs on injured workers and ultimately provide a mechanism for them to get back to work sooner.

Watson Pharmaceuticals announces limited recall of Fentanyl transdermal patches

Watson Pharmaceuticals, Inc. has announced that one lot of 75 mcg/hr Fentanyl Transdermal System patches sold in the United States is being voluntarily recalled from wholesalers and pharmacies.

Evolutionary principles of natural selection may be applied to successfully manage cancer

According to researchers at Moffitt Cancer Center, cancer is subject to the evolutionary processes laid out by Charles Darwin in his concept of natural selection. Natural selection was the process identified by Darwin by which nature selects certain physical attributes, or phenotypes, to pass on to offspring to better "fit" the organism to the environment.

Warfarin and PT-INR testing: an interview with Paul Wright, CEO, Universal Biosensors

There are roughly 10 million people worldwide taking Warfarin, accounting for more than 200 million point of care (POC) PT-INR tests performed globally each year...

Arnold L Alper, MD - Ophthalmology in Amherst, MA